A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.

开始日期2011-11-01

申办/合作机构

ApoPharma, Inc.

100 项与 Orilotimod potassium 相关的临床结果

登录后查看更多信息

100 项与 Orilotimod potassium 相关的转化医学

登录后查看更多信息

100 项与 Orilotimod potassium 相关的专利（医药）

登录后查看更多信息

项与 Orilotimod potassium 相关的文献（医药）

Journal of Inflammation Research

C/EBPβ Promotes LPS-Induced IL-1β Transcription and Secretion in Alveolar Macrophages via NOD2 Signaling

Article

作者: Zhang, Yibo ; Zhang, Guixin ; Wen, Haiyun ; Liu, Jin ; Lan, Bowen ; Dong, Xuanchi ; Ge, Peng ; Yang, Qi ; Luo, Yalan ; Chen, Hailong

ObjectiveC/EBPβ, a crucial transcription factor, regulates innate immunity and inflammatory responses. However, the role played by C/EBPβ in alveolar macrophage (AM) inflammatory responses remains unknown. This study aimed to investigate the role and mechanism of C/EBPβ in alveolar macrophages (AMs) from the transcriptional level and to search for natural compounds targeting C/EBPβ.MethodsRat AMs were infected with Lv-sh-C/EBPβ and treated with LPS, and the expression levels of iNOS, TNF-α, IL-6, and IL-1β were measured by RT-qPCR, Western blotting, and ELISA. Mechanistically, transcriptome sequencing (RNA-seq) revealed changes in gene expression patterns in AMs after LPS stimulation and C/EBPβ knockdown. Functional enrichment analyses and rescue experiments identified and validated inflammation-associated cell signaling pathways regulated by C/EBPβ. Furthermore, virtual screening was used to search for natural compounds that inhibit C/EBPβ with the structure of helenalin as a reference.ResultsFollowing stimulation with LPS, AMs exhibited an increased expression of C/EBPβ. C/EBPβ knockdown significantly decreased the expression levels of inflammatory mediators. A total of 374 differentially expressed genes (DEGs) were identified between LPS-stimulated C/EBPβ knockdown and negative control cells. The NOD-like receptor signaling may be a key target for C/EBPβ, according to functional enrichment analyses of the DEGs. Further experiments showed that the muramyl dipeptide (MDP, NOD2 agonist) reversed the downregulation of inflammatory mediators and the NF-κB pathway caused by the C/EBPβ knockdown. The virtual screening revealed that N-caffeoyltryptophan, orilotimod, and petasiphenone have comparable pharmacological properties to helenalin (a known C/EBPβ inhibitor) and demonstrate a great binding capacity to C/EBPβ.ConclusionAblation of C/EBPβ may attenuate LPS-induced inflammatory damage in AMs by inhibiting the NOD2 receptor signaling pathway. Three natural compounds, N-caffeoyltryptophan, orilotimod, and petasiphenone, may be potential C/EBPβ inhibitors.

100 项与 Orilotimod potassium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10720	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斑块状银屑病	临床2期	加拿大	ApoPharma, Inc.	2011-11-01
斑块状银屑病	临床2期	美国	ApoPharma, Inc.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01483924 (CTgov)	临床2期	斑块状银屑病	60	placebo (Placebo)	製鬱願夢選艱築艱蓋願(製餘夢餘壓遞壓鏇夢蓋) = 廠夢醖齋範選遞範選積鏇鑰築鬱築艱簾壓壓艱 (醖鬱選醖憲鬱獵範壓夢, 糧蓋鬱鏇範觸獵糧範鹽 ~ 積淵簾顧憲顧膚鏇遞齋) 更多	-	2015-02-20
				Apo805K1 (Apo805K1 10 mg)	製鬱願夢選艱築艱蓋願(製餘夢餘壓遞壓鏇夢蓋) = 鑰齋願膚蓋壓鹹壓觸艱鏇鑰築鬱築艱簾壓壓艱 (醖鬱選醖憲鬱獵範壓夢, 艱窪淵鬱願簾窪窪選糧 ~ 夢遞簾窪壓網積顧夢簾) 更多